Please complete the CAPTCHA to continue
@svhealthinvestors.com
✓
2 phones found area 212
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Jonathan Behr is listed as Investing in, and building, life science companies at Dementia Discovery Fund, based in Cambridge, Massachusetts, United States. AeroLeads shows a work email signal at svhealthinvestors.com, phone signal with area code 212, and a matched LinkedIn profile for Jonathan Behr.
Jonathan Behr previously worked as Partner at Dementia Discovery Fund and Partner at Sv Health Investors. Jonathan Behr holds Phd, Biological Engineering from Massachusetts Institute Of Technology.
This section adds company-level context without repeating Jonathan Behr's masked contact details.
AeroLeads found 1 current-domain work email signal for Jonathan Behr. Compare company email patterns before reaching out.
Life science and healthcare investor and entrepreneur with operating experience.
Listed skills include Biotechnology, Start Ups, Venture Capital, Lifesciences, and 40 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
London, England, GB
The Dementia Discovery Fund (DDF) is a venture capital fund, delivering both high-impact therapeutics for age related dementias and financial returns by investing in, creating, and supporting innovative companies. I am responsible for helping to build the Fund’s investment portfolio by leading investments in new and established companies, working closely.
London, England, GB
The Parkinson’s UK Virtual Biotech (VB) programme was established in 2016 as a patient-led programme to discover and develop new treatments for Parkinson’s. It represents a core element of the strategy of the Parkinson’s UK charity (the “Charity”) to accelerate breakthroughs in research. Parkinson's Research Ventures (PRV) is a wholly-owned subsidiary of.
Cambridge, MA, US
Director, Chair of the Transaction Committee, member of the Compensation Committee. Merck (NYSE: MRK) acquired Caraway Therapeutics for a total potential consideration of up to $610 million.
Boston, Massachusetts, US
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private.
Executive Director level manager responsible for shaping and executing mission-driven Partners HealthCare Innovation (http://innovation.partners.org/) based commercial offerings and strategy in key priority areas or market sectors. I lead and manage 9 licensing professionals organized into market sector teams, focused on creating commercial strategies and.
Using the power of immunology to develop new treatments for cancer, fibrosis and autoimmunity. Acquired by MRK in 2019.
Entrega makes injectable substances available orally. As co-founder and COO of Entrega I closed a multi-million dollar R&D collaboration with Google[x], led the licensing negotiations and transaction, was responsible for long-term strategy and day-to-day operations, and managed multiple R&D alliances with major pharmaceutical companies..
Cambridge, MA, US
Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. As a co-founder, sourced and licensed technologies, assembled Scientific Advisory Boards, created IP and IP strategy, and secured funding from PureTech for microbiome related initiatives.
Mandara was founded by PureTech and a team of experts in the food and nutrition industry to deliver health through nutrition. As a co-founder, I collaborated in crafting the initial company strategy and in raising funding from a major corporate partner. http://www.mandarasciences.com/
Tal is developing breakthrough neuromodulation treatment for psychiatric disorders. As a co-founder, I sourced and evaluated technologies, led the licensing negotiations and transaction, and created IP and long-term strategy. http://www.talmedical.com/
I led and participated on teams identifying, evaluating, creating, operating, and partnering life science investment opportunities and start-up companies with major pharmaceutical companies. Enlight is a Boston-based company established in partnership with major pharmaceutical companies (MRK, PFE, LLY, JNJ, ABT, AZN, NVO) to develop breakthrough.
Boston, Massachusetts, US
As a Principal at PureTech Ventures (now PureTech Health, http://puretechhealth.com/, LON:PRTC) I led the creative conceptualization, technology identification, diligence, in-licensing, and business development activities necessary to create and fund innovative biotechnology companies. I was a founding team member of >5 companies including Enlight, Endra.
Ann Arbor, MI, US
Endra, Inc. (NASDAQ:NDRAU) is commercializing a breakthrough medical imaging technology that combines the properties of light-based (optical) imaging with ultrasound, based on the principles of photoacoustics. As a co-founder, I sourced and licensed technologies, assembled scientific advisers, managed academic collaborations, and created IP and company.
Venture backed company which raised >$15M to develop innovative treatments for pain.
Houston, Texas, US
Bethesda, MD, US
Quick answers generated from the profile data available on this page.
Jonathan Behr works for Dementia Discovery Fund.
Jonathan Behr is listed as Investing in, and building, life science companies at Dementia Discovery Fund.
AeroLeads has found 1 work email signal at @svhealthinvestors.com for Jonathan Behr at Dementia Discovery Fund.
AeroLeads has found 2 phone signal(s) with area code 212 for Jonathan Behr at Dementia Discovery Fund.
Jonathan Behr is based in Cambridge, Massachusetts, United States while working with Dementia Discovery Fund.
Jonathan Behr has worked for Dementia Discovery Fund, Sv Health Investors, Sudo Biosciences, Montara Therapeutics, Inc., and Violet Therapeutics.
You can use AeroLeads to view verified contact signals for Jonathan Behr at Dementia Discovery Fund, including work email, phone, and LinkedIn data when available.
Jonathan Behr holds Phd, Biological Engineering from Massachusetts Institute Of Technology.
Jonathan Behr is listed with skills including Biotechnology, Start Ups, Venture Capital, Lifesciences, Business Development, Drug Discovery, Business Strategy, and Strategy.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts